These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
234 related items for PubMed ID: 9096609
1. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. al Rayyes O, Wallmark A, Florén CH. Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609 [Abstract] [Full Text] [Related]
2. Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells. Al Rayyes O, Wallmark A, Florén CH. Hepatology; 1997 Oct; 26(4):967-71. PubMed ID: 9328321 [Abstract] [Full Text] [Related]
3. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver. Ness GC, Lopez D, Chambers CM, Zhao Z, Beach DL, Ko SS, Trzaskos JM. Arch Biochem Biophys; 1998 Sep 15; 357(2):259-64. PubMed ID: 9735166 [Abstract] [Full Text] [Related]
4. Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Rayyes OA, Wallmark A, Florén CH. Hepatology; 1996 Sep 15; 24(3):613-9. PubMed ID: 8781333 [Abstract] [Full Text] [Related]
5. Stimulation of the proliferation of the Madin-Darby canine kidney (MDCK) epithelial cell line by high-density lipoproteins and their induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Gospodarowicz D, Cohen DC, Massoglia SL. J Cell Physiol; 1983 Oct 15; 117(1):76-90. PubMed ID: 6352714 [Abstract] [Full Text] [Related]
6. Lactacystin increases LDL receptor level on HepG2 cells. Miura H, Tomoda H, Miura K, Takishima K, Omura S. Biochem Biophys Res Commun; 1996 Oct 23; 227(3):684-7. PubMed ID: 8885994 [Abstract] [Full Text] [Related]
7. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription. Mascaró C, Ortiz JA, Ramos MM, Haro D, Hegardt FG. Arch Biochem Biophys; 2000 Feb 15; 374(2):286-92. PubMed ID: 10666309 [Abstract] [Full Text] [Related]
8. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. J Cardiovasc Pharmacol; 1998 Jan 15; 31(1):39-45. PubMed ID: 9456275 [Abstract] [Full Text] [Related]
9. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation". Yu L, Qiu S, Genest J. Atherosclerosis; 1996 Jul 15; 124(1):103-17. PubMed ID: 8800498 [Abstract] [Full Text] [Related]
10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I, Spinler SA, Johnson NE. Ann Pharmacother; 1995 Jul 15; 29(7-8):743-59. PubMed ID: 8520093 [Abstract] [Full Text] [Related]
11. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS, Bacon SP, Illingworth DR. J Lab Clin Med; 2003 Apr 15; 141(4):250-6. PubMed ID: 12677170 [Abstract] [Full Text] [Related]
12. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity in mouse peritoneal macrophages. Angelin B. Biochem J; 1988 Oct 15; 255(2):529-34. PubMed ID: 3202831 [Abstract] [Full Text] [Related]
13. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Johnston TP, Palmer WK. Pharmacotherapy; 1997 Oct 15; 17(2):342-7. PubMed ID: 9085326 [Abstract] [Full Text] [Related]
14. Effects of hypocholesterolaemic agents on the expression and activity of 3-hydroxy-3-methylglutaryl-CoA reductase in the fat body of the German cockroach. Zapata R, Martín D, Piulachs MD, Bellés X. Arch Insect Biochem Physiol; 2002 Apr 15; 49(4):177-86. PubMed ID: 11921076 [Abstract] [Full Text] [Related]
15. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Ness GC, Zhao Z, Lopez D. Arch Biochem Biophys; 1996 Jan 15; 325(2):242-8. PubMed ID: 8561503 [Abstract] [Full Text] [Related]
16. Differing effects of three oxysterols on low density lipoprotein metabolism in HepG2 cells. Pinkerton FD, Spilman CH, Via DP, Schroepfer GJ. Biochem Biophys Res Commun; 1993 Jun 30; 193(3):1091-7. PubMed ID: 8391799 [Abstract] [Full Text] [Related]
17. Induction of low-density lipoprotein catabolism in Hep G2 cells by a fungal sesquiterpene ester, FR111142. Harada T, Hasumi K, Endo A. Biochem Biophys Res Commun; 1998 Oct 29; 251(3):830-4. PubMed ID: 9790995 [Abstract] [Full Text] [Related]
18. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase unmask transcriptional regulation of hepatic low-density lipoprotein receptor gene expression by dietary cholesterol. Lopez D, Ness GC. Arch Biochem Biophys; 1997 Aug 01; 344(1):215-9. PubMed ID: 9244400 [Abstract] [Full Text] [Related]
19. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment. Moghadasian MH, Nguyen LB, Shefer S, Salen G, Batta AK, Frohlich JJ. Metabolism; 2001 Jun 01; 50(6):708-14. PubMed ID: 11398149 [Abstract] [Full Text] [Related]
20. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. Hughes AD. J Hum Hypertens; 1996 Jun 01; 10(6):387-90. PubMed ID: 8872802 [Abstract] [Full Text] [Related] Page: [Next] [New Search]